Recombinant interferon alfa-2b/Loratadine

重组干扰素α-2b/氯雷他定

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant interferon alfa-2b/Loratadine
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionHistamine H1 receptor antagonistsImmunostimulantsInnate antiviral immune response inducers +[4] 
TargetsHistamine H1 receptorInterferon alpha/beta receptor
Therapy Area/IndicationsConjunctivitis, AllergicRhinitis, Allergic
Global Approved IndicationsConjunctivitis, AllergicRhinitis, Allergic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2013/08/01
Country/TerritoryRussian Federation
CombinationsYes LoratadineInterferon alfa-2b (Merck Sharp & Dohme)
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFirn M Zao
China Registration ClassN/A

Develop Information

Active CompaniesFirn M Zao
Inactive CompaniesN/A
Active IndicationsConjunctivitis, AllergicRhinitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeL03AB
Related LinksN/A